A retrospective study evaluate the safety of SC Daratumumab in patients with multiple myeloma (MM) and light-chain amyloidosis (AL)
Latest Information Update: 28 Jul 2021
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab
- Indications Amyloid light-chain amyloidosis; Multiple myeloma
- Focus Adverse reactions
- 28 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology